Recursion shareholders approve stock issuance for Exscientia acquisition

RECURSION PHARMACEUTICALS, INC.

Shareholders voted 99.77% in favor (250.9M votes for) of issuing Class A common stock for the Exscientia acquisition.
Proposal 2 (adjournment) deemed unnecessary after approval; not presented at Special Meeting.
Special Meeting held Nov 12, 2024; quorum achieved with 253.5M votes present (72.5% of total eligible).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.